1.48
前日終値:
$1.37
開ける:
$1.45
24時間の取引高:
1.32M
Relative Volume:
4.90
時価総額:
$35.54M
収益:
-
当期純損益:
$-21.54M
株価収益率:
-1.4943
EPS:
-0.9904
ネットキャッシュフロー:
$-19.60M
1週間 パフォーマンス:
-10.57%
1か月 パフォーマンス:
+32.14%
6か月 パフォーマンス:
-51.48%
1年 パフォーマンス:
-83.03%
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Compare ACTU vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ACTU
Actuate Therapeutics Inc
|
1.48 | 29.54M | 0 | -21.54M | -19.60M | -0.9904 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-26 | 開始されました | B. Riley Securities | Buy |
| 2025-04-22 | 開始されました | Craig Hallum | Buy |
| 2025-03-17 | 開始されました | H.C. Wainwright | Buy |
Actuate Therapeutics Inc (ACTU) 最新ニュース
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn
Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada
Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - Vinanet
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics (ACTU) Pushes 3.58% Higher, Tests $1.06 Resistance ZoneButterfly Setup - dars.gov.et
Actuate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) Holds Near $0.97 as Support Test LoomsButterfly Setup - vinanet.vn
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentEarnings Outlook Update - Vinanet
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
ETFs Investing in Actuate Therapeutics, Inc. Stocks - TradingView
Actuate Therapeutics Inc (ACTU) Stock News Today - TradingKey
Actuate Therapeutics (ACTU) Surges 8.85% to $1.23 as Buyers Defend Key SupportOvernight Profile - vinanet.vn
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Actuate Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACTU - TradingView
Rodman & Renshaw Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $6 - Moomoo
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw - Investing.com
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.170|Chg%:-0.010 - TradingKey
Actuate Therapeutics Inc (ACTU) Cash Flow - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.230|Chg%:+0.170 - TradingKey
Actuate Therapeutics Inc (ACTU) Balance Sheet - TradingKey
Actuate Therapeutics Inc (ACTU) Income Statement - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.140|Chg%:-0.040 - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.185|Chg%:-0.075 - TradingKey
Actuate Therapeutics Inc (ACTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Actuate Therapeutics (ACTU) Faces Selling Pressure as Stock Slides to $1.26MFI Oversold - dars.gov.et
Actuate Therapeutics Inc. (ACTU) Q1 2026 Earnings: EPS Miss of 8.6% Reflects Continued Pre-Revenue Investment PhaseEPS Guidance Update - dars.gov.et
Actuate Therapeutics, Inc. Files Form 8-K: NASDAQ Compliance Update and Company Details (July 2026) - Minichart
Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ACTU Q1 2026 Earnings: EPS Misses Estimates as Stock Declines 13%EPS Consistency Score - vinanet.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Actuate Therapeutics (ACTU) Surges 17.8% as Momentum Builds After Support TestLow Risk Entry Stocks - vinanet.vn
ACTU Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock RallyDividend Growth Analysis - dars.gov.et
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Dynamic Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000E Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2500 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 3000 Index - marketscreener.com
Actuate Therapeutics, Inc.(NasdaqGM: ACTU) dropped from Russell 2000 Index - marketscreener.com
Actuate Therapeutics Inc (ACTU) 財務データ
収益
当期純利益
現金流量
EPS
Actuate Therapeutics Inc (ACTU) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SCHMITT DANIEL M | President, CEO and Director |
Feb 13 '26 |
Option Exercise |
0.00 |
272,055 |
0 |
272,055 |
| THOMSON TODD S | Director |
Jan 05 '26 |
Sale |
5.80 |
280,000 |
1,624,000 |
904,795 |
大文字化:
|
ボリューム (24 時間):